GBS, Inc. (GBS)
| Market Cap | 53.86M |
| Revenue (ttm) | 441,754 |
| Net Income (ttm) | n/a |
| Shares Out | 11.80M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $4.28 |
| Previous Close | $4.36 |
| Change ($) | -0.08 |
| Change (%) | -1.83% |
| Day's Open | 4.29 |
| Day's Range | 4.13 - 4.30 |
| Day's Volume | 75,695 |
| 52-Week Range | 2.44 - 14.24 |
Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?
Global results show 90% of patients are in favor of a saliva-based glucose test Global results show 90% of patients are in favor of a saliva-based glucose test
- Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021-
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biolog...
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary heal...
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their prima...
GBS and Inhibikase Therapeutics priced late Tuesday.
Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”
Will Trade on the Nasdaq Global Market Under Ticker “GBS”
GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to r...
About GBS
GBS is a biosensor diagnostic technology company operating worldwide with our COV2 test and across the APAC Region with the biosensor platform comprising of biochemistry, immunology, tumour markers, hormones and nucleic acid diagnostic modalities. We were incorporated under the laws of Delaware on December 5, 2016. Our headquarters are located in New York, New York. GBS is the global licensee and intends to introduce and launch COV2 diagnostic tests across the US, Europe, APAC and the rest of the world through appropriately qualified distributo... [Read more...]
| Industry Medical Devices | IPO Date Dec 23, 2020 |
| CEO Harry Simeonidis | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol GBS |
Financial Performance
In 2020, GBS, Inc.'s revenue was $188,841, an increase of 100,347.34% compared to the previous year's $188. Losses were -$3.13 million, -57.27% less than in 2019.